Bilal A Siddiqui, MD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
In the News
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | Yale School of Medicine, New Haven, CT, USA, MD, Medicine |
| 2011 | Harvard University, Cambridge, MA, USA, AB, Molecular and Cellular Biology |
Postgraduate Training
| 2018-2021 | Clinical Fellowship, Hematology / Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2016-2018 | Clinical Residency, Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA |
| 2015-2016 | Clinical Internship, Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA |
Board Certifications
| 2021 | American Board of Internal Medicine- Medical Oncology |
| 2021 | American Board of Internal Medicine- Hematology |
| 2018 | American Board of Internal Medicine- Internal Medicine |
Honors & Awards
| 2023 | ASCO Career Development Award, ASCO Foundation |
| 2023 | 2023 Regeneron-PCF Special Challenge Award, Prostate Cancer Foundation |
| 2022 | PCF Young Investigator Award, Prostate Cancer Foundation |
| 2021 | Waun Ki Hong Award for Achievement in Clinical Investigation, MD Anderson Cancer Center |
| 2021 | Humanitas Award, MD Anderson Cancer Center |
| 2021 | Finalist, Rolanette and Berdon Lawrence Research Award Competition, Bone Disease Program of Texas |
| 2020 | First Prize, Poster Presentation Award, Annual Multi-Institutional Prostate Cancer Program Retreat |
| 2020 | NIH Loan Repayment Program, NIH |
| 2020 | The Harter Prize for Excellence in Clinical Training Research, MD Anderson Cancer Center |
| 2019 | NIH T32 Grant, MD Anderson Cancer Center |
| 2012 | Medical Student Research Fellowship, Yale School of Medicine |
| 2011 | Magna cum laude, Harvard University |
| 2009 | Harvard College Scholar, Harvard University |
Selected Publications
Peer-Reviewed Articles
- Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw:1-8. e-Pub 2024. PMID: 38190801.
- Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Soroush-Rais-Bahrami , Bathala T, Chapin BF. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol 25(1):66-83, 2024. e-Pub 2024. PMID: 38212510.
- Viscuse PV, Slack-Tidwell RS, Zhang M, Rohra P, Zhu K, San Lucas FA, Konnick E, Pilie PG, Siddiqui B, Logothetis CJ, Corn P, Subudhi SK, Pritchard CC, Soundararajan R, Aparicio A. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers (Basel) 15(24), 2023. e-Pub 2023. PMID: 38136389.
- Pizuorno Machado A, Shatila M, Glitza Oliva IC, Altan M, Siddiqui BA, Zhou Y, Varatharajalu K, Zhang HC, Thomas A, Wang Y. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. Am J Clin Oncol 46(8):360-365, 2023. e-Pub 2023. PMID: 37219360.
- Thomas AR, Liu C, Tong YT, Tan D, Altan M, Siddiqui BA, Shatila M, Khan A, Thomas AS, Wang Y. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. J Cancer Res Clin Oncol 149(8):5429-5436, 2023. e-Pub 2022. PMID: 36451045.
- Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor. J Immunother Cancer 11(3), 2023. PMID: 36948506.
- Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, Durand JB, Deswal A, Zhao B, Maximilian Buja L, Iliescu C. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail 23(10):1725-1735, 2021. e-Pub 2021. PMID: 34114291.
- Subudhi SK*, Siddiqui BA*, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10), 2021. PMID: 34663638.
- Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
- Lehner MJ, Gheeya JS, Siddiqui BA, Tummala S. Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients. J Neurooncol 153(3):441-446, 2021. e-Pub 2021. PMID: 34076832.
- Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. PMID: 34326169.
Invited Articles
- Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652-1669, 2023. PMID: 37059068.
- Hahn AW, Siddiqui BA, Leo J, Dondossola E, Basham KJ, Miranti CJ, Frigo DE. Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer. Endocrinology 164(6), 2023. PMID: 37192413.
- Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. PMID: 33811120.
- Siddiqui BA, Zhang M, Pisters LL, Tu SM. Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment. Transl Androl Urol 9(Suppl 1):S56-S65, 2020. PMID: 32055486.
Editorials
- Siddiqui BA, Subudhi SK, Sharma P. Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Rep Med 19;3(4):100613, 2022. PMID: 35492243.
- Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell 40(3):249-251, 2022. PMID: 35290784.
Book Chapters
- Sharma, P., Anandhan, S., Siddiqui, B.A., Goswami, S., Sharma, A., Subudhi, S.K., Gao, J.J., Peggs, K., Quezada, S., Allison, J.P.. Cancer Immunotherapy. In: Cancer Medicine. 10th. Wiley-Blackwell, 2023.
- Siddiqui B.A, Goswami S., Allison J.P., Sharma P.. Immuno-Oncology. In: In: The MD Anderson Manual of Medical Oncology. 4th Edition. McGraw Hill, 2022.
- Roberts, R., Siddiqui, B.A., Subudhi, S.K., Sheth, R.A.. Image-Guided Biopsy/Liquid Biopsy. In: Image-Guided Interventions in Oncology. Springer, 2020.
Patient Reviews
CV information above last modified July 16, 2024